Charles River Laboratories International, Inc. (USD) Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc. (USD) Active

251 Ballardvale Street, Wilmington, MA, US, 01887

Stock Price USD

Price Change

Last Dividend USD

Latest Rating

CRL's stock peer is AVTR (Avantor, Inc.)

CRL's stock peer is BAX (Baxter International Inc.)

CRL's stock peer is BIO (Bio-Rad Laboratories, Inc.)

CRL's stock peer is CAI (Caris Life Sciences, Inc.)

CRL's stock peer is PEN (Penumbra, Inc.)

CRL's stock peer is RNA (Atrium Therapeutics, Inc.)

CRL's stock peer is RVTY (Revvity, Inc.)

Healthcare Medical - Diagnostics & Research

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

60%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

60%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated le.

2026-06-18 08:00:00

Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Sidoti Small-Cap Virtual Conference on June 17 and 18, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 10:00 a.m. EDT on Wednesday, June 17. A live webcast will be available on the Company's investor relations website. An archived replay will be avai.

2026-06-03 08:30:00

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.

2026-05-13 08:00:00

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.

2026-05-11 08:00:00

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fiscal first quarter ended April 4, 2026. “Maintaining the momentum of a record fiscal 2025, CRA continued its strong performance into the first quarter of fiscal 2026 as revenue increased by 10.5% year over year to $201.0 million,” said Paul Maleh, CRA's President and Chief Executive Officer. “This re.

2026-05-07 08:05:00

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.57 per common share to be paid on June 12, 2026 to shareholders of record of CRA's common stock as of the close of business on May 26, 2026. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain sub.

2026-05-07 08:00:00

Charles River Laboratories Announces First-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.

2026-05-07 07:00:00

Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated.

2026-04-30 08:00:00

Charles River Associates (CRA) to Host First-Quarter Fiscal 2026 Financial Results Conference Call on May 7

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the company will webcast its first-quarter 2026 financial results conference call on Thursday, May 7, 2026 at 10:00 a.m. ET. The conference call will be hosted by President and Chief Executive Officer Paul Maleh, Chief Financial Officer Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes. To listen to a l.

2026-04-23 08:30:00

Charles River Highlights Effectiveness of VCGs in Toxicology

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoin.

2026-04-21 08:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions